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Summary
 Background Severe bacterial and fungal infection remains a persistent cause of morbidity and 
mortality in severely neutropenic patients undergoing intensive chemotherapy 
and/or haematopoietic stem cell transplantation
 Aim To analyze granulocyte source, collection and storage as well as clinical efﬁ cacy 
and toxicity of modern granulocyte transfusions for treatment of severe bacte-
rial and fungal infections in neutropenic patients undergoing intensive chemo-
therapy and/or haematopoietic stem cell transplantation.
 Materials/Methods A review of PubMed references based on evidence-based recommendations and 
own experience.
 Results A single dose regimen of subcutaneous G-CSF plus oral dexamethasone admin-
istered 12 hours prior to leukapheresis appears to be a cost-effective regimen for 
mobilizing granulocytes from normal donors. Modern continuous ﬂ ow centrifu-
gation is used to collect granulocytes, whilst a sedimenting agent such as hydroxy-
ethyl starch removes erythrocytes. If required storage at 10°C rather than 22°C 
better preserves function of collected granulocytes for up to 24 hours. Peters et 
al. (1999) treated 30 children for documented infection, with just over half re-
ceiving G-CSF stimulated donor granulocytes. In this series 82% of bacterial and 
54% of fungal infections responded. In the Netherlands 18 children have been 
treated with granulocyte transfusions. In children with established infection 75% 
responded. Transfusion reactions associated with mobilized granulocyte transfu-
sions are similar to other blood components, and are generally mild.
 Conclusions Modern granulocyte transfusions are a relatively safe albeit controversial modal-
ity of treatment. Reasonable indications are resistant severe bacterial infection 
with no response to antibiotics and localized fungal infections in neutropenic 
patients as well as neutropenic typhilitis. The efﬁ cacy in treating or preventing 
sepsis remains to be established in prospective controlled trials. Within the pae-
diatric setting, literature other than in neonates is relatively sparse and deserves 
further clinical studies.
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BACKGROUND
Severe bacterial and fungal infection remains a 
persistent cause of morbidity and mortality in se-
verely neutropenic patients undergoing intensive 
chemotherapy and/or haematopoietic stem cell 
transplantation.[1,2]
Early trials of granulocyte transfusions (GTs) 
demonstrated variable efﬁ cacy, mainly due to 
variation in the number of granulocytes infused, 
as well as improved antibiotic regimens for rel-
atively good risk patients, which obfuscated any 
potential clinical advantage.[3,4] These and re-
ports of adverse effects in the granulocyte trans-
fused patients [5] led to the idea that GTs were 
expensive and ineffective.
MATERIALS AND METHODS
References were retrieved using the online 
database of the National Library of Medicine 
(PubMed; http://www.ncbi.nlm.nih.gov/PubMed). 
Terms used included: granulocyte transfusion, 
neutropenic children, bacterial and fungal in-
fections. The retrieved references were supple-




Historically, large doses of cells were obtained 
from patients with chronic myeloid leukaemia 
and defervescence of infection was related to the 
number of granulocytes administered.[6] This 
clinical observation was also evident in the ne-
onatal setting where the cell dose per kilogram 
body weight was much higher.[7]
Methodological improvements, especially G-CSF 
to stimulate normal donors and improvements in 
continuous ﬂ ow separation, erythrocyte sedimen-
tation techniques and storage, have resulted in a 
process whereby sufﬁ cient blood neutrophils (up 
to 80×109) can be released for potentially effective 
control of life-threatening infections.[8,9]
A single dose regimen of subcutaneous G-CSF 
plus oral dexamethasone administered 12 hours 
prior to leukapheresis appears to be a cost-effec-
tive regimen for mobilizing granulocytes from 
normal donors.[10] Although community donors 
could be used [11], most blood transfusion cen-
tres have used relatives as the donor source.
Granulocyte collection and storage
Modern continuous ﬂ ow centrifugation is used 
to collect granulocytes, [12] whilst a sedimenting 
agent such as hydroxy-ethyl starch removes eryth-
rocytes. Presently granulocytes are collected and 
administered daily with minimal time delays be-
tween collection and transfusion. Recent studies 
suggest that, if necessary, storage at 10°C rather 
than 22°C better preserves function of collected 
granulocytes for up to 24 hours. [13]
DISCUSSION
Clinical efﬁ cacy of transfused granulocytes
Although it is evident that large doses of granu-
locytes can be collected after mobilization and 
that infusion results in an increased patient neu-
trophil count with apparently normal function, 
the proof that this therapy is clinically useful has 
not yet been established. To date evidence derives 
only from clinical reports or uncontrolled series. 
A phase III randomized trial is currently seeking 
approval within the USA, which aims to recruit 
over 200 patients over 3–4 years. [14]
In 1995, Strauss analyzed the then published re-
sults of GTs in neutropenic patients. Overall, 62% 
of 206 patients with bacterial sepsis apparently ben-
eﬁ ted from GTs, whereas 71% of 63 patients with 
invasive fungal infections reportedly did not.
In subsequent studies where higher levels of mo-
bilized granulocytes were transfused, therapeutic 
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outcome of bacterial sepsis was generally fa-
vourable. Results in patients with invasive fun-
gal infections varied depending on the study 
[11,15–17].
Peters and colleagues treated 30 children for doc-
umented infection, with just over half receiving G-
CSF stimulated donor granulocytes. In this series 
82% of bacterial and 54% of fungal infections re-
sponded.[18] In the Netherlands we have adopt-
ed a national protocol for children, which to date 
has treated 18 children with 21 courses of GTs. In 
children with established infection (n=16), 75% 
responded. Four children received pre-emptive 
GTs pre-allogeneic or autologous transplantation 
(two of whom had received previous GTs in the 
treatment group). No disseminated infection was 
recorded in this high-risk group.[19]
Toxicity of granulocyte transfusions
Transfusion reactions associated with mobilized 
GTs are similar to other blood components and 
are generally mild. Mobilized GTs may transmit 
infectious diseases; thus blood donor counsel-
ling and screening are mandatory to eliminate 
high-risk donors.
Recent studies have not documented pulmonary 
reactions with G-CSF mobilized granulocytes even 
in patients receiving Amphotericin B or its lipo-
somal formulation.
Allo-immunization to HLA-class I and/or granu-
locyte speciﬁ c antigens are a concern [20]. Rapid 
allo-immunization seems less common in the se-
verely immuno-suppressed [9]. Current practice 
is to test for ABO antigen compatibility and leu-
co-agglutination prior to GTs. Acute GVHD from 
infusion of immune competent donor T cells can 
be reduced by irradiation (15–30Gy) immediate-
ly prior to administration.
CONCLUSIONS
Modern GTs are a relatively safe albeit contro-
versial modality of treatment. Reasonable indi-
cations are resistant severe bacterial infection 
with no response to antibiotics and localized fun-
gal infections in neutropenic patients as well as 
neutropenic typhilitis. The efﬁ cacy in treating 
or preventing sepsis remains to be established 
in prospective controlled trials. Within the pae-
diatric setting, literature other than in neonates 
is relatively sparse and deserves further clinical 
studies.
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